Cardioimmunology and Heart Transplantation

Abstract

A new interest in cardiac immunology is the result of the recent ability to diagnose and obtain unbiased data on heart cells with high cytogenetic resolution. This is rare and is believed to be missing 10 years ago. The adopted immune system focuses on traditional immunosuppression. Increased awareness of innate immunity has many potentials, blocking the response of Toll-like receptors to I/R damage, depleting or blocking NK cell activation, and interfering with complement activation and deposition. Suggests therapeutic goals. Given the remarkable advances in diagnosis and care that have emerged over the last few decades, the essential pathogenic signaling pathways are not well understood and significantly limit the effectiveness of therapeutic treatment. This chapter aims to broaden our knowledge of the factors performed by the immune system in ischemic heart disease, non-ischemic myocarditis, ejection fraction-maintained heart failure, endocarditis, and conduction disorders. increase. Many features of innate and adaptive immune cells are mobilized by ischemic injury, and the function of immunity in myocarditis is still being studied. In addition, the chemokine community regulates the transport of immune cells at specific stages of homeostasis and inflammation, and chemokines, along with some sclerosis, bronchial asthma, AIDS, and even transplants, are inflammatory reactions caused by T cell-related diseases. Rejection mechanisms that may be mentioned in five major titles have been specifically studied. Immunization, immunological memory, cell memory, humoral memory, antibody secretion, opsonization, and supplement cascade activation.